Authors
Latest:
Individualized Approach to Treatment for the Elderly Ovarian Cancer PatientStuart Lichtman, MD, and William Tew, MD, from Memorial Sloan-Kettering Cancer Center, discuss personalizing treatment for elderly patients with ovarian cancer.
Latest:
Chemobrain-It's Real, It's Complex, and the Science Is Still EvolvingTalk with almost any cancer survivor, and she/he is likely to bring up the topic of "chemobrain," that fuzzy, murky state that patients blame for impaired memory.
Latest:
New Oncology Care Model Reforms Payment System, Offers Performance-Based IncentivesThe CMS announced the launch of an Oncology Care Model that contains goals and incentives for practitioners in cancer care.
Latest:
Whole-Blood, 6-Gene Prognostic Signature May Help Personalize Prostate Cancer TreatmentDrs William Oh and Yixuan Gong discuss their research involving a whole-blood, 6-gene prognostic signature that has the potential to help personalize prostate cancer treatment.
Latest:
Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.
Latest:
Dr. Lee on Data Regarding HIPEC in mCRCByrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate clinical professor of surgical oncology, Department of Surgery, and surgical oncologist, City of Hope, discusses data regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with metastatic colorectal cancer (mCRC).
Latest:
Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal CancerStudies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer
Latest:
NOW Initiative: Payer & Provider Collaborations in Oncology Benefits ManagementPayers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.
Latest:
Dr. Osborne on Evaluating HER2 Positivity in Breast CancerC. Kent Osborne, MD, discusses the important take home message for physicians treating patients with HER2-positive breast cancer. Osborne says the role of HER2-positivity is complicated.
Latest:
Looking at the Latest Data in Multiple Myeloma and Lymphoma From ASH 2023: Drs Landgren and SaeedOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Latest:
Dr. Gibbs on Testing for p16 and p21 in OsteosarcomaC. Parker Gibbs Jr, MD, discusses how to test for p16 and p21 in patients with osteosarcoma.
Latest:
Dr. Gibbs on the Lack of Treatment Options in SarcomaC. Parker Gibbs Jr, MD, discusses the lack of treatment options for patients with soft tissue and bone sarcomas.
Latest:
Treatment Considerations and Sequencing in Multiple MyelomaThe expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.
Latest:
Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast CancerGrowing attempts to develop biomarkers to guide therapy within triple-negative breast cancer may lead to more effective regimens or to novel therapeutic targets.
Latest:
Dr. May on Olaratumab Activity in Pediatric Bone and Soft Tissue SarcomaCaitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.
Latest:
Preclinical Activity With Olaratumab in SarcomaCaitlin May, PhD, postdoctoral research scientist at Eli Lilly and Company, discusses preclinical activity with olaratumab (Lynparza) in pediatric sarcoma models.
Latest:
Dr. Gunderson on the Use of PARP Inhibitors in All-Comers With Ovarian CancerCamille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.
Latest:
Perspectives on the Hematology-Oncology Fellowship JourneyCandace Haddox, MD, and Narjust Duma, MD, address the uncertainty, the victories, and the defeats common in oncology fellowship programs.
Latest:
Dr. Anders on Navigating the Treatment Landscape of Metastatic TNBCCarey K. Anders, MD, discusses navigating the treatment landscape of metastatic triple-negative breast cancer.
Latest:
Dr. Anders on the Lessons Learned From the OlympiA Trial in BRCA-Mutated Breast CancerCarey K. Anders, MD, discusses lessons learned from the phase 3 OlympiA trial in BRCA-mutated breast cancer.
